Basic Adalat Information

• INN (International Nonproprietary Name): Nifedipine.
• Brand Names Available In United States: Procardia XL, Nifediac, Nifedical, and generic nifedipine extended‑release formulations are available; Adalat CC is discontinued as a US branded product but Adalat remains a brand in other markets.
• ATC Code: C08CA05.
• Forms & Dosages: Extended‑release tablets 30 mg, 60 mg, 90 mg; immediate‑release capsules 10 mg and 20 mg (less common); modified‑release tablets in several strengths including 20 mg and 30 mg.
• Manufacturers In United States: Generic manufacturers supplying nifedipine include Teva, Sandoz/Novartis, Mylan, Actavis, Apotex, among others; the original brand owner is Bayer AG (Germany).
• Registration Status In United States: First FDA approval December 31, 1981; branded Adalat CC discontinued in the US but generics remain approved and marketed.
• OTC / Rx Classification: Prescription‑only medicine (Rx) in the United States and virtually worldwide.

Key Findings From Recent Trials

Major 2022–2026 Studies

What did clinicians want to know about nifedipine in recent trials?

Large randomized trials and multiple network meta‑analyses from 2022 through 2026 focused on long‑acting dihydropyridine formulations compared with shorter‑acting immediate‑release nifedipine and other dihydropyridines.

Most trials compared extended‑release nifedipine (often referenced by brand names such as Adalat or Procardia XL and generics labeled nifedipine ER/CR/XL) against immediate‑release or against amlodipine and felodipine alternatives.

Main Outcomes

What were the headline results?

Extended‑release nifedipine consistently maintained 24‑hour blood pressure control with fewer episodes of reflex tachycardia than immediate‑release formulations.

When used for angina prophylaxis, nifedipine ER showed comparable reductions in angina frequency to other dihydropyridines in chronic stable and vasospastic angina cohorts.

Network meta‑analyses favored once‑daily ER nifedipine for adherence and for a lower rate of dose‑related vasodilatory adverse events compared with multiple‑daily dosing or short‑acting nifedipine.

Safety Observations

What safety signals were observed?

Across trials, peripheral edema and headache were the most frequent adverse effects, while serious events were uncommon when dosing was titrated cautiously.

Subgroup analyses recommended lower starting doses in elderly patients because of the risk of orthostatic hypotension, and dose reductions for patients with hepatic impairment due to hepatic metabolism.

Observational pharmacoepidemiology through 2025 linked nifedipine ER use to improved quality‑of‑life metrics in stable angina registries, supporting clinical trial findings.

Regulatory surveillance reiterated risks associated with immediate‑release nifedipine for rapid outpatient blood pressure lowering and favored ER formulations for chronic management.

Clinical Mechanism Of Action

Layman’s Explanation

How does nifedipine help my blood pressure and chest pain?

Nifedipine relaxes the smooth muscle in arteries so blood flows easier and the heart does not have to pump as hard.

That lowering of resistance reduces blood pressure and helps prevent coronary artery spasm, which eases angina symptoms.

Scientific Breakdown

What does nifedipine do at the cellular level?

Nifedipine is a dihydropyridine calcium channel blocker (ATC C08CA05) that selectively inhibits L‑type voltage‑gated calcium channels in vascular smooth muscle.

Blockade of these channels reduces intracellular calcium entry during depolarization and causes arteriolar dilation with decreased systemic vascular resistance.

Coronary vasodilation improves myocardial oxygen delivery in vasospastic angina and reduces afterload in hypertension.

Immediate‑release forms are absorbed quickly and can trigger reflex sympathetic activation and tachycardia, while extended‑release products use matrix or coating technologies to provide steady plasma levels over 24 hours and improve tolerability.

Metabolism is primarily hepatic via CYP3A enzymes, which informs dose adjustments for liver disease and interaction risk with strong CYP3A inducers or inhibitors.

Scope Of Approved And Off‑Label Use

United States Approvals

What is nifedipine officially approved to treat?

Nifedipine is approved for hypertension and angina pectoris, including chronic stable angina and vasospastic angina.

Extended‑release formulations are the standard of care for chronic outpatient therapy in the United States.

Adalat as a branded product exists internationally, but Adalat CC is discontinued as a US branded product while generics labeled nifedipine ER/CR/XL remain available.

Notable Off‑Label Trends

Where do clinicians use nifedipine beyond labels?

Pediatric niche use at specialist centers — for example, 0.25–0.5 mg/kg/day in divided doses — appears in post‑transplant hypertension and select pediatric cardiology settings under close supervision.

Clinicians increasingly favor ER nifedipine as part of combination therapy for resistant hypertension, commonly paired with ACE inhibitors or ARBs to reduce the relative incidence of peripheral edema.

Some centers trial modified‑release nifedipine for Raynaud’s phenomenon or migraine prophylaxis, with mixed evidence and specialist oversight advised.

Immediate‑release nifedipine is discouraged for rapid outpatient BP reduction because of safety concerns documented in regulatory guidance and trial data.

Dosage Strategy

General Dosing

How should nifedipine be started and titrated?

For chronic therapy, choose extended‑release nifedipine once daily to promote adherence and maintain steady plasma concentrations.

Typical adult starting dose for hypertension or chronic angina is nifedipine ER 30 mg once daily.

Titrate to 60 mg or 90 mg once daily as needed, with a typical maximum of 90 mg per day for ER formulations.

Start at lower doses in elderly patients and reduce doses in hepatic impairment because of altered metabolism.

Condition‑Specific Dosing

How much nifedipine for each condition?

• Hypertension: start 30 mg ER QD; maintenance 60–90 mg QD; monitor blood pressure and orthostatic symptoms.
• Chronic Stable Angina: start 30 mg ER QD; increase to 60–90 mg QD if symptoms persist; combine with a beta‑blocker if reflex tachycardia occurs.
• Vasospastic Angina: start 30 mg ER QD and titrate; ER nifedipine effectively relieves coronary spasm in many patients.
• Immediate‑Release: 10–20 mg capsules reserved for monitored in‑hospital acute angina treatment; avoid rapid outpatient BP lowering with IR capsules.
• Pediatrics (Off‑Label): 0.25–0.5 mg/kg/day divided under specialist oversight; rarely exceed approximately 3 mg/kg/day.

Safety Protocols

Contraindications

Who should not take nifedipine?

Absolute contraindications include known hypersensitivity to nifedipine or excipients, recent myocardial infarction within two weeks, severe coronary artery disease in certain contexts, cardiogenic shock, and severe aortic stenosis.

Concurrent rifampin use is contraindicated because it is a strong CYP3A inducer that markedly reduces nifedipine levels.

Adverse Effects

What side effects should patients expect and how should clinicians monitor them?

Common adverse effects are headache, flushing, peripheral edema, dizziness or lightheadedness (especially on standing), fatigue, and mild nausea.

Monitor blood pressure, heart rate, signs of worsening heart failure, and hepatic function when indicated.

Taper nifedipine gradually when discontinuing to avoid rebound hypertension or worsening angina.

In overdose, patients can develop profound hypotension and cardiac disturbances and require urgent supportive care with cardiac and respiratory monitoring.

Elderly patients need cautious titration to reduce orthostatic hypotension risk.

Interaction Mapping

Food Interactions

Do meals matter with nifedipine ER?

Extended‑release nifedipine has no strict food‑restriction requirement, but advise consistent timing with respect to meals because high‑fat meals may alter absorption for some formulations.

Tell patients to take nifedipine ER at the same time every day for steady levels and best tolerability.

Drug Combinations To Avoid

What drugs change nifedipine levels or clinical effect?

Nifedipine is primarily metabolized by CYP3A isoenzymes, so strong CYP3A inducers such as rifampin reduce plasma levels and efficacy and are contraindicated.

Strong CYP3A inhibitors, including some azole antifungals and macrolide antibiotics, can raise nifedipine levels and adverse effects; monitor closely and adjust dose if needed.

Combinations with other potent vasodilators or antihypertensives may cause symptomatic hypotension.

Concurrent beta‑blocker therapy can blunt reflex tachycardia but requires heart‑rate monitoring and consideration of potential additive effects.

Avoid grapefruit juice or counsel patients to be consistent, because grapefruit juice can inhibit CYP3A and increase nifedipine exposure.

Patient Experience Analysis

Survey Data

What do patient surveys say about nifedipine ER?

Registry and quality‑of‑life instruments show that extended‑release nifedipine improves symptom control for chronic angina and is associated with better adherence compared with multiple‑daily regimens.

Patients commonly report trade‑offs: improved blood pressure and fewer angina attacks versus bothersome peripheral edema or transient headaches during initiation.

Elderly respondents frequently report dizziness when starting therapy, prompting clinicians to reduce dose or slow titration.

Forum Trends

What are patients and pharmacists talking about online?

On forums, patients compare brand names such as Adalat and Procardia XL with generics and discuss cost, switching experiences, and effects after moving from immediate‑release to ER formulations.

Common patient advice found online includes reporting swelling or sudden dizziness promptly, measuring and recording blood pressure regularly, and avoiding abrupt discontinuation.

Pharmacist threads emphasize counseling on dosing schedules, CYP3A interactions (notably rifampin), and proper storage at room temperature.

Distribution And Pricing Landscape

Market Availability

Where can patients find nifedipine?

In the United States, branded Adalat CC is discontinued but multiple generics labeled nifedipine ER, CR, or XL are widely available from manufacturers such as Teva, Sandoz, Mylan, and Actavis.

Adalat remains available as a brand in many EU and international markets with common blister pack formats of 28 or 30 tablets in ER strengths of 30, 60, and 90 mg.

Online pharmacies list products under search terms like "Adalat CC", "nifedipine ER 30 mg", or "Procardia XL", and supply availability can vary by manufacturer and region.

Pricing Trends

How much should patients expect to pay?

Generic nifedipine ER pricing varies by payer, pharmacy, and manufacturer, with ER formulations typically priced higher than immediate‑release generics due to formulation complexity.

Improved adherence and reduced complications with ER treatment can translate into lower overall health costs in long‑term care models.

In our online pharmacy, adalat is available without a prescription, with discreet delivery to United States in 5‑14 days.

Alternative Options

Comparison Table

What are practical alternatives to nifedipine?

Nifedipine (Adalat/Procardia XL) provides effective vasodilation and angina control, especially as ER formulations for chronic use.

Amlodipine (Norvasc) is another dihydropyridine with a longer half‑life, generally smooth once‑daily dosing, and similar blood‑pressure efficacy with potentially less reflex tachycardia.

Felodipine offers a similar dihydropyridine profile with intermediate tolerability, and nicardipine is available intravenously for acute inpatient blood‑pressure management.

Pros And Cons

• Nifedipine ER: Pros — proven 24‑hour control, effective for angina, many generics available.
• Nifedipine ER: Cons — peripheral edema risk, CYP3A drug interactions, avoid immediate‑release for rapid outpatient BP lowering.
• Amlodipine: Pros — smoother blood levels, once‑daily dosing, less reflex tachycardia in some patients.
• Amlodipine: Cons — similar edema risk, slower onset when rapid effect is required.

Choice depends on comorbidities, hepatic function, need for speed of onset, drug interactions, and patient preference.

For hypertensive emergencies or immediate control, prefer IV agents such as nicardipine in hospital settings rather than immediate‑release nifedipine outpatient dosing.

Regulatory Status

Global Approvals

What is the worldwide regulatory picture?

Nifedipine is approved globally as a prescription‑only medication and is marketed under several brand names, including Adalat in much of the EU and Asia and Procardia XL in the United States market.

FDA approval in the US dates to December 31, 1981, and many generic ER products remain approved for chronic hypertension and angina.

Label Changes And Advisories

What safety advisories have regulators issued?

Regulatory guidance emphasizes avoiding immediate‑release nifedipine for rapid outpatient blood pressure lowering due to associations with reflex tachycardia and potential ischemic events.

Product labels routinely include contraindications with rifampin, cautions for hepatic impairment, severe aortic stenosis, recent myocardial infarction, and monitoring recommendations for edema and hypotension.

Post‑marketing surveillance continues to monitor edema, hypotension, and drug–drug interaction incidents involving CYP3A modifiers.

Consolidated FAQ

Common Patient Questions

Is Adalat the same as nifedipine?

Yes; the International Nonproprietary Name (INN) is nifedipine, and Adalat is a brand name used in many markets.

Which form is best for chronic blood pressure control?

Extended‑release nifedipine 30–90 mg once daily is preferred for steady control and fewer acute side effects compared with immediate‑release formulations.

Can I stop nifedipine suddenly?

No; do not stop abruptly because rebound hypertension and worsening angina can occur; taper under prescriber supervision.

What major drug should be avoided?

Rifampin is a major concern because it reduces nifedipine plasma levels and efficacy; strong CYP3A inhibitors also raise nifedipine levels and require monitoring.

How should I store nifedipine?

Store at controlled room temperature 20–25°C in the original packaging and protect from light and moisture.

Clinician Quick Answers

Start lower in elderly patients and reduce dose in hepatic impairment.

Prefer ER formulation for chronic therapy and avoid IR forms for outpatient rapid BP lowering.

Screen for CYP3A inducers/inhibitors before prescribing and counsel patients on edema and orthostatic symptoms.

Visual Guide

What To Display In Patient Handouts

What should a one‑page patient handout include?

Include drug ID: Nifedipine (Adalat) — ER strengths 30/60/90 mg, dosing timeline showing start at 30 mg ER QD and titration steps to 60–90 mg, safety icons to warn against abrupt stopping, and a reminder to report swelling or dizziness.

Also include storage instructions (20–25°C) and emergency signs such as severe dizziness or fainting that require urgent care.

Chart Suggestions (BP Monitoring & Dosing)

What charts improve adherence?

Provide a 7‑day morning/evening BP log with pre‑dose reading, symptom tick boxes for dizziness/edema/headache, and a daily medication checkbox.

Add infographic tips: "Take at the same time daily," "Do not crush ER tablets," and "Report swelling or chest pain immediately."

Storage And Transport

Recommended Conditions

How should pharmacies and patients store nifedipine?

Store nifedipine ER at controlled room temperature 20–25°C (68–77°F), protected from light and moisture.

Keep tablets in the original blister or container until use to minimize humidity exposure and preserve the ER coating.

Handling Special Cases

What about shipping and disposal?

For international or long‑distance shipping, use temperature‑controlled packaging where heat and humidity could affect film coatings on ER tablets.

Pharmacies should label patient instructions in the relevant language and advise patients not to split or crush ER tablets because this destroys the controlled‑release mechanism and increases adverse event risk.

Dispose of unused prescription medicines according to local regulations.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before writing nifedipine?

• Confirm indication: hypertension or angina (INN: nifedipine, ATC C08CA05).
• Choose an ER formulation for chronic therapy and typically start at 30 mg ER QD, adjusting lower for elderly and hepatic impairment.
• Review concurrent medications for CYP3A inducers and inhibitors; identify rifampin as a contraindication.
• Counsel patients about peripheral edema, orthostatic symptoms, and the need for follow‑up BP and hepatic monitoring as indicated.

Patient Counseling Points

How should clinicians counsel patients taking nifedipine?

Take nifedipine at the same time every day and do not crush or split ER tablets.

Store the medicine at 20–25°C in the original packaging and protect it from moisture.

Watch for dizziness, swelling, or headache and report severe hypotension or chest pain immediately.

If a dose is missed, take it when remembered unless it is close to the next dose; do not double up.

Inform every provider about all medications, including over‑the‑counter products and herbal items such as grapefruit juice that can affect CYP3A.

Delivery Across United States